FDC Limited (NSE: FDC) is a leading Indian pharmaceutical company that specializes in the manufacturing and marketing of a wide range of prescription and OTC drugs. The company has a strong presence in India and exports its products to more than 50 countries. FDC Limited has a diversified product portfolio that includes various therapeutic segments such as anti-infectives, gastroenterology, dermatology, cardiology, and ophthalmology.
In terms of earnings, Revenue from Operations for Q3 FY23 was ₹409.29 crore, a 20% increase from ₹341.78 crore in the same period last year. The third quarter’s other income, which contributed ₹18.40 Crore to the Total Revenue. Meanwhile, the Profit Before Tax improved to ₹56.58 Crore from ₹50.75 Crore from the same quarter previous year. The Consolidated Net Profit was ₹40.71 crore, up 14% from ₹35.61 crore in the same quarter last year. This quarter’s earnings per share was ₹2.45. In the same time period, the company’s Tax Expense increased up to ₹15.87 Crore from ₹15.14 Crore.